Skip to main content
Caplight Logo









KaloCyte, Inc.

KaloCyte, Inc.

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://kalocyte.com/

Last Round

Seed

Feb 24, 2025

Total Funding Raised

$24.13M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

KaloCyte, Inc. is a biotechnology company developing ErythroMer™, a dried, bio-inspired artificial red blood cell substitute for use when stored red blood cells are unavailable.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

artificial bloodblood substitutesynthetic bloodoxygen carriernanoparticle encapsulationtrauma careemergency medicineshelf-stable bloodbiosynthetic hemoglobinbattlefield medicinefreeze-dried bloodcombat casualty carepre-hospital carebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KaloCyte, Inc. Comparables

Compare KaloCyte, Inc. with similar companies based on industry and business-model similarity.

KaloCyte, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VirTech Bio
85%
NanoBlood LLC
85%
Fluoro2 Therapeutics
82%

KaloCyte, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 24, 2025
GrantFeb 1, 2025
GrantJan 28, 2025
GrantApr 15, 2024
GrantAug 22, 2023
Debt
Jul 17, 2023

Key People

Founding team and executive leadership

Elaine Haynes

President And CEO, Board Director

Executive Team

Akunna Iheanacho

Fractional Chief Operating Officer

Executive Team

KaloCyte, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 114% MoM.

  • Feb 24, 2025

    $2.6M round led by Ferocity Capital

KaloCyte, Inc. Filings

Explore SEC and related filing metadata, where available.

KaloCyte, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about KaloCyte, Inc.'s valuation, stock price, and market status.

Is KaloCyte, Inc. a public or private company?

KaloCyte, Inc. is a private company.

What is the current stock price of KaloCyte, Inc.?

KaloCyte, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is KaloCyte, Inc. worth (valuation)?

Valuation information for KaloCyte, Inc. is not publicly available.

Can I buy KaloCyte, Inc. stock?

KaloCyte, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was KaloCyte, Inc.'s last funding round?

KaloCyte, Inc.'s most recent funding round was Grant on April 15, 2024.

Who are the main investors in KaloCyte, Inc.?

Key investors in KaloCyte, Inc. include NIH RADx, TEDCO, Old Line Capital Partners, University System of Maryland Momentum Fund, Defense Advanced Research Projects Agency.

Will KaloCyte, Inc. IPO soon?

No public IPO plans have been announced for KaloCyte, Inc..

How can I track KaloCyte, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor KaloCyte, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range18
Year Founded2016
Last FundingFeb 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?